Recent Updates
Recently added Catalysts

TJ037130

Phase 1

Solid Tumor | Small molecule | Oncology |Biogen Inc.|Trials Updated: Jul 20, 2026

TJ037130 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Jul 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment128

FDA Designations

No designations recorded

TJ037130 clinical trials

TJ037130 · 1 trial · 4 indications

Phase 1 1
NCT07715747A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsSolid Tumor
NOT YET_RECRUITING128 Analytics
PHASE1NOT YET_RECRUITING
A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
Solid Tumor
NCT07715747128
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence,type,severity and correlation with study treament of AEs
Up to 90 days post last dose

Secondary Endpoints

Pharmacokinetic (PK) Parameters: AUCt
Up to 90 days post last dose
Pharmacokinetic (PK) Parameters: Cmax
Up to 90 days post last dose
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TJ037130EXPERIMENTAL -

Interventions

NameTypeDescription
TJ037130DRUGDose Escalation:TJ037130 will be administered at up to 5 dose levels(0.75,2,5,10 and 18mg/kg) once 3 weeks(Q3W); During dose expansion, TJ037130 will be administered once 3 weeks in 4 Cohorts.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Males or females aged 18 years or older; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * Voluntarily enroll in the study and be able to comply with scheduled visits, treatment schedules, laboratory tests and other study procedures; * Participants wi...

Countries:China
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Solid Tumor")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK3PHASE2Pembrolizumab, Gardasil 9
Incyte CorporationINCY1PHASE2Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115
Iovance Biotherapeutics IncIOVA2PHASE2Aldesleukin
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Biogen Inc. (BIIB)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with TCompanies A to ZEvery biotech and pharma company we track